Company Reports

Yakult reported revenue growth of 3.3% year over year for fiscal year 2026, ending March 2027, supported by 16% overseas growth that offset a 7.2% decline in domestic revenue. Robust growth drove Asia and Oceania operating margins up to 9.3% versus 4.3% a year ago.

Research and development in probiotics, primarily in beverage products and pharmaceuticals, has laid the foundation for Yakult. Its flagship products are probiotic drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy under its new midterm plan to 2030.

Yakult's fourth-quarter fiscal 2025 (ended March 2026) revenue of JPY 115 billion increased 1% year over year. Although revenue in Japan declined by 8%, it was offset by overseas revenue growing 12%. Management guidance is for a 2.6% decline in operating income to JPY 44 billion for fiscal 2026.

Research and development in probiotics, primarily in beverage products and pharmaceuticals, has laid the foundation for Yakult. Its flagship products are probiotic drinks marketed under the namesake brand in 40 countries across four continents, make up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy under its new midterm plan to 2030.

Yakult's fiscal third-quarter (ended December 2025) revenue of JPY 130 billion was down 0.4% from last year. Operating margin fell 100 basis points due to operating deleverage in Japan. Fiscal 2025 operating profit guidance of JPY 48.5 billion was kept. We transfer coverage to a new analyst.

Research and development in probiotics, primarily in beverage products and pharmaceuticals, has laid the foundation for Yakult Honsha. Its flagship products are probiotic drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Research and development in probiotics, primarily in beverage products and pharmaceuticals, has laid the foundation for Yakult Honsha. Its flagship products are probiotic drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Domestic sales remained sluggish as Yakult's fiscal second-quarter operating income dropped 21.1% from a year ago. Management lowered operating income guidance again for fiscal 2025 (ending March 2026) to JPY 48.5 billion from JPY 53.5 billion.

Due to sluggish domestic sales, Yakult's fiscal first-quarter reported operating income dropped 35.8% from a year ago to JPY 10.9 billion. Management lowered operating income guidance for fiscal 2025 (ending March 2026) to JPY 53.5 billion from JPY 58.5 billion.

Research and development in probiotics, primarily in beverage products and pharmaceuticals, has laid the foundation for Yakult Honsha. Its flagship products are probiotic drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Yakult Honsha's results for the March quarter were disappointing. Operating income of JPY 4.6 billion fell short of our expectation of JPY 8.5 billion as well as the JPY 7.5 billion in the year-ago quarter. Weak domestic sales and higher marketing costs continued to hurt margins. Although revenue in the Americas and Europe remained strong due to solid shipments and a weaker yen, this was not enough to offset the weakness in Japan. Despite the short-term headwinds, we are encouraged by Yakult’s new midterm plan, which intends to enhance profitability and capital efficiency through strategic investments and increased shareholder returns. Therefore, we maintain our JPY 3,250 fair value estimate. We believe the shares are about fairly valued.

Research and development in probiotics has laid the foundation for Yakult Honsha, primarily comprising beverage products and pharmaceuticals. The flagship products are probiotics drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Narrow-moat Yakult’s fiscal third-quarter results were below our estimates due to margin pressure in the domestic market. Overseas markets served as a partial offset thanks to growing volume and currency tailwinds. We fractionally lowered our fiscal 2024 (ending March 2025) operating profit estimate as we raised our fourth-quarter profit projection in overseas regions with the expectation that momentum will continue. We also maintain our 2025-28 forecasts for operating profit. As a result, we have left our fair value estimate unchanged at JPY 3,250 per share, which implies 19 times fiscal 2025 price/earnings, 10 times enterprise value/EBITDA, and a 2.1% free cash flow dividend. We view the shares as undervalued, but near-term sentiment could be suppressed by uncertainty around the domestic business.

Research and development in probiotics has laid the foundation for Yakult Honsha, primarily comprising beverage products and pharmaceuticals. The flagship products are probiotics drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/ Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Research and development in probiotics has laid the foundation for Yakult Honsha, primarily comprising beverage products and pharmaceuticals. The flagship products are probiotics drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/ Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Narrow-moat Yakult Honsha reported fiscal 2025 (ending March 31, 2025) second-quarter results that disappointed across revenue and profits. Management cut its fiscal-year guidance following sluggish volume across Japan and China as well as higher promotional expenses that dampened the profit outlook. While our previous projection was already below company guidance, we lowered our operating profit estimates further to JPY 60.7 billion, which is a touch below updated guidance of JPY 61.5 billion. We think volume weakness and elevated selling expenses will persist in the near term. We also reduced our 2025-28 operating profit estimates by 2%-5% and raised the weighted average cost of capital assumption to 6.4% from 5.3%. Therefore, we've lowered our fair value estimate by 14% to JPY 3,250 per share. We think near-term sentiment over the stock could remain weak.

Narrow-moat Yakult’s first-quarter sales volume significantly fell short of its annual target. Yet, price hikes, coupled with rigorous cost control and favorable currency movement, capped the profit decline at 5.2% year on year. Strength in Americas offset the persistent weakness in Asia. The preliminary second-quarter volume data indicate that volume contraction started narrowing in China thanks to the successful new product launch. We expect volume decline will continue to lessen given the easier comparison base, but the pace of recovery will largely hinge on the real wage growth in the core markets. We maintained our projections. Given the recent correction, we view shares, trading at a 30% discount to our fair value estimate of JPY 3,800, as undervalued. Whether the volume decline will cease in China and Japan in coming quarters is critical to restoring the market’s confidence, in our view.

Research and development in probiotics has laid the foundation for Yakult’s business, primarily comprising beverage products and pharmaceuticals. The flagship products are probiotics drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/ Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.

Narrow-moat Yakult missed its profit guidance as expected but the fourth-quarter operating profit came in 11% below our forecast, as the decline in Yakult 1000 volume accelerated to a mid-teen percentage in March despite a 20% boost in production capacity in the quarter. Likewise, volume continued to contract at a double-digit pace in China and Indonesia although the decline narrowed quarter on quarter. We have finetuned our assumptions, which leave an immaterial impact on our fair value estimate of JPY 3,800. Whether the new initiatives in China and marketing campaigns for Yakult 1000/Y1000 in Japan will reverse the downward volume trend will be our focus. We continue to view Yakult's shares, trading at a 20% discount to our intrinsic value, as undervalued, but we acknowledge that the negative volume trend in core markets will continue to weigh on the near-term share performance.

Research and development in probiotics has laid the foundation for Yakult’s business, primarily comprising beverage products and pharmaceuticals. The flagship products are probiotics drinks marketed under the namesake brand in 40 countries across four continents, making up an estimated 80% of group sales and 90% of profits. Expanding the international footprint and enhancing domestic profitability through premiumization are the two pillars of Yakult’s growth strategy. Domestic growth lifted by the premium Yakult 1000/ Y1000 success has taken up the baton from overseas volume expansion, becoming a key profit driver.